CAS: 36476-78-5; Azetidine-3-Carboxylic Acid

相似化合物

102624-96-4 142253-55-2 193693-64-0

上下游产品

CAS号94985-27-0 1-苄基氮杂环丁烷-3-甲酸 | CAS号26096-30-0 (1-benzylazetid... | CAS号87-69-4 酒石酸 | CAS号343238-58-4 3-甲酸甲酯氮杂环丁烷盐酸盐 | CAS号875629-26-8 1-甲基-3-氮杂丁烷羧酸 | CAS号97628-92-7 1-(苄氧基羰基)氮杂丁烷-3-羧酸 | CAS号1001026-41-0 1-(2,2,2-triflu... | CAS号100202-39-9 氮杂环丁烷-3-甲酸甲酯盐酸盐 | CAS号142253-55-2 1-B°C-氮杂环丁烷-3-羧酸

1-N-Boc-3-吖丁啶羧酸置于palladium 10% On Activated Carbon,氢气体系中,用 乙醇 用作溶剂,50.0 °C,2.5 Mpa 条件下,反应 30.0H,以13.8 G的收率获得3-吖丁啶羧酸
参考文献:氮杂环羧酸中间体及氮杂环丁烷-3-羧酸的制备方法
标题:氮杂环羧酸中间体及氮杂环丁烷-3-羧酸的制备方法
摘要:本发明公开了氮杂环羧酸中间体及氮杂环丁烷‑3‑羧酸的制备方法,涉及医药化工技术领域.用于制备氮杂环丁烷‑3‑羧酸的氮杂环羧酸中间体的制备方法包括:将氮杂环化合物和wittig反应试剂混合进行wittig反应并分离得到氮杂环甲醛中间体;将氮杂环甲醛中间体进行氧化反应并分离得到氮杂环羧酸中间体;其中,氮杂环化合物选自1‑二苯甲基‑3‑氮杂环丁酮,1‑苄基氮杂环丁烷‑3‑酮,1‑boc氮杂环丁烷‑3‑酮和1‑乙酰基氮杂啶‑3‑酮中的至少一种.氮杂环丁烷‑3‑羧酸的制备方法是将氮杂环羧酸中间体进行氢解,生产周期短,制备过程安全可靠,生产成本低,纯度大于98%,收率可以达到82.8%.

专利信息

专利号:US-9938509-B2
优先权日:2010-12-08
标 题 :Biocatalysts and methods for the synthesis of armodafinil
发明人：ANG EE LUI; ALVIZO OSCAR; BEHROUZIAN BEHNAZ; CLAY MICHAEL D; COLLIER STEVEN J; EBERHARD ELLEN D; FAN FU; SONG SHIWEI; SMITH DEREK J; WIDEGREN MAGNUS; WILSON ROBERT; XU JUNYE; ZHU JUN
权利人:CODEXIS INC
摘要:The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

专利号:US-11401273-B2
优先权日:2018-11-20
标题:Asymmetric synthesis of Azaspiro compounds
发明人：LELETI RAJENDER REDDY; WAMAN YOGESH; KALLURE PRIYA; BEGUM ZUBEDA; DIVYA THUMBAN; NALIVELA KUMARA SWAMY; VIJAY SAURABH; PARIKH PARANJAY; KOTTURI SHARADSRIKAR; PATEL CHIRAG; NAYAK KRISHNA; BAHAROONI KASIMRAZA; ZALAVADIYA VINKAL
权利人:PIRAMAL PHARMA LTD
摘要:The present invention relates to an improved asymmetric synthesis of azaspiro or diazaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the formation of intermediate compounds 4, (4A) or (4N) respectively. The process comprises an unusual substrate specific highly diastereoselective as well as enantio-enriched 1-substituted 2-azaspiro[3.3]heptane or 1-substituted 2-diazaspiro[3.3]heptane compounds with high diastereoselectivity by addition of a cyclobutane carboxylate anion to a Davis-Ellman's imine, followed by reduction and cyclisation resulting in the selective formation of azaspiro or diazaspiro intermediate compound 4, (4A) or (4N); which on subsequently removing the sulfinyl group provides corresponding azaspiro or diazaspiro compound 5, (5A) or (5N) respectively.

专利号:US-2025091989-A1
优先权日:2023-09-19
标 题 :Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-9663771-B2
优先权日:2013-01-18
标题 :Engineered biocatalysts useful for carbapenem synthesis
发明人：SUKUMARAN JOLY; SMITH DEREK; YANG HONG; YEO WAN LIN; MOORE JEFFREY C
权利人:CODEXIS INC
摘要:The present disclosure provides engineered pNB esterase polypeptides useful for the synthesis of the carbapenem antibiotic, imipenem. The disclosure also provides polynucleotides encoding the engineered pNB esterases, host cells capable of expressing the engineered pNB esterases, and methods of using the engineered pNB esterases in the production of imipenem.

专利号:US-2023391818-A1
优先权日:2020-11-05
标 题:Peptide synthesis method for suppressing defect caused by diketopiperazine formation
发明人：NOMURA KENICHI; KAGE MIRAI; TAMIYA MINORU; KANAZAWA JUNICHIRO
权利人:CHUGAI PHARMACEUTICAL CO LTD
摘要:Solid-phase synthesis of a peptide has a problem that a desired elongation reaction is prevented from proceeding by diketopiperazine and a 6-membered diamine skeleton compound formed when a protective group at the N-terminal is removed. The present inventors have found that when in production of a peptide by a solid-phase method, a peptide in which an amino group at the N-terminal is protected with a protective group having an Fmoc skeleton is treated in a specific solvent with a base having a pKa of 23 or more in acetonitrile as a conjugate acid, and a peptide chain is then elongated, it is possible to solve the problem described above.

专利号:WO-2018108954-A1
优先权日:2016-12-12
标题 :Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
发明人：GOSSELIN FRANCIS; LINGHU XIN
权利人:HOFFMANN LA ROCHE; GENENTECH INC
摘要:Methods of making 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol 9, an intermediate useful for the synthesis of estrogen receptor modulating compounds are described.